SERTRALINE

Search structure
Synonyms:
Status: Approved (1991)
Entry Type: Small molecule
Molecule Category: Parent
ATC: N06AB06
UNII: QUC7NX6WMB

Structure
InChI Key VGKDLMBJGBXTGI-SJCJKPOMSA-N
Smile CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
InChI
InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H17Cl2N
Molecular Weight 306.24
AlogP 5.18
Hydrogen Bond Acceptor 1.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 2.0
Polar Surface Area 12.03
Molecular species BASE
Aromatic Rings 2.0
Heavy Atoms 20.0

Pharmacology

Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 1 Cytochrome P450 family 1A Cytochrome P450 1A2
- 29700 - - -
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C19
- 310-22500 - - -
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6
- 1400-2880 - - -
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- 800-13600 - - -
Enzyme
- 1400-2880 - - -
Ion channel Voltage-gated ion channel Voltage-gated calcium channel
- 2310-2600 - - -
Membrane receptor
- - - 57 -
Transcription factor
- 27000 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC06 neurotransmitter transporter family
- 0-3 0 1-3 -
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 29340 - - -
Unclassified protein
- - - 5297 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Depressive Disorder 4 D003866 ClinicalTrials
Depressive Disorder 4 D003866 ClinicalTrials
Anxiety Disorders 3 D001008 ClinicalTrials
Bipolar Disorder 3 D001714 ClinicalTrials
Schizophrenia 3 D012559 ClinicalTrials
Stress Disorders, Post-Traumatic 3 D013313 ClinicalTrials
Autistic Disorder 3 D001321 ClinicalTrials
Obsessive-Compulsive Disorder 3 D009771 ClinicalTrials
Sleep Initiation and Maintenance Disorders 3 D007319 ClinicalTrials
Anxiety 3 D001007 ClinicalTrials
Meningitis, Cryptococcal 3 D016919 ClinicalTrials
Phobia, Social 3 D000072861 ClinicalTrials
Dementia 3 D003704 ClinicalTrials
Depressive Disorder, Major 3 D003865 ClinicalTrials
Alcoholism 2 D000437 ClinicalTrials
Brain Injuries 2 D001930 ClinicalTrials
Mood Disorders 2 D019964 ClinicalTrials
Panic Disorder 2 D016584 ClinicalTrials
Fragile X Syndrome 2 D005600 ClinicalTrials
Pruritus 2 D011537 ClinicalTrials
Coccidioidomycosis 2 D003047 ClinicalTrials
Alcoholism 2 D000437 ClinicalTrials
Depression, Postpartum 2 D019052 ClinicalTrials
Cocaine-Related Disorders 2 D019970 ClinicalTrials
Child Development Disorders, Pervasive 2 D002659 ClinicalTrials
Substance-Related Disorders 2 D019966 ClinicalTrials
Glioblastoma 1 D005909 ClinicalTrials
Hepatitis C 1 D006526 ClinicalTrials
Obesity 1 D009765 ClinicalTrials
Leukemia, Myeloid, Acute 1 D015470 ClinicalTrials
Myelodysplastic Syndromes 1 D009190 ClinicalTrials

Related Entries

Scaffolds

Salt

Cross References

Resources Reference
CAS NUMBER 79617-96-2
ChEBI 9123
ChEMBL CHEMBL809
DrugBank DB01104
DrugCentral 2436
EPA CompTox DTXSID6023577
FDA SRS QUC7NX6WMB
Human Metabolome Database HMDB0005010
Guide to Pharmacology 4798
KEGG C07246
PDB SRE
PharmGKB PA451333
PubChem 68617
SureChEMBL SCHEMBL28701
ZINC ZINC000001853550
CONTENTS